FI3544972T3 - Heteroaryylifenoksibentsamidi-kappa-opioidiligandeja - Google Patents
Heteroaryylifenoksibentsamidi-kappa-opioidiligandeja Download PDFInfo
- Publication number
- FI3544972T3 FI3544972T3 FIEP17818281.2T FI17818281T FI3544972T3 FI 3544972 T3 FI3544972 T3 FI 3544972T3 FI 17818281 T FI17818281 T FI 17818281T FI 3544972 T3 FI3544972 T3 FI 3544972T3
- Authority
- FI
- Finland
- Prior art keywords
- pyrazol
- benzamide
- pyrrolidin
- ylmethyl
- phenoxy
- Prior art date
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title claims 76
- 239000003446 ligand Substances 0.000 title 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 235000019000 fluorine Nutrition 0.000 claims 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 239000011737 fluorine Substances 0.000 claims 6
- 206010012335 Dependence Diseases 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 4
- 208000012902 Nervous system disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 235000014632 disordered eating Nutrition 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 208000020016 psychiatric disease Diseases 0.000 claims 4
- 229960000581 salicylamide Drugs 0.000 claims 4
- 208000011117 substance-related disease Diseases 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 3
- 208000030814 Eating disease Diseases 0.000 claims 3
- 206010013663 drug dependence Diseases 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 238000001237 Raman spectrum Methods 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 102000048260 kappa Opioid Receptors Human genes 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 208000012672 seasonal affective disease Diseases 0.000 claims 2
- 108020001588 κ-opioid receptors Proteins 0.000 claims 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000029197 Amphetamine-Related disease Diseases 0.000 claims 1
- 102000014461 Ataxins Human genes 0.000 claims 1
- 108010078286 Ataxins Proteins 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 244000025254 Cannabis sativa Species 0.000 claims 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 1
- 208000027691 Conduct disease Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 1
- 206010013754 Drug withdrawal syndrome Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 238000005079 FT-Raman Methods 0.000 claims 1
- 208000010235 Food Addiction Diseases 0.000 claims 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020710 Hyperphagia Diseases 0.000 claims 1
- 208000030990 Impulse-control disease Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 208000010428 Muscle Weakness Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 208000002033 Myoclonus Diseases 0.000 claims 1
- 208000027626 Neurocognitive disease Diseases 0.000 claims 1
- 206010057852 Nicotine dependence Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 1
- 208000006199 Parasomnias Diseases 0.000 claims 1
- 206010034158 Pathological gambling Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 208000029808 Psychomotor disease Diseases 0.000 claims 1
- 238000001069 Raman spectroscopy Methods 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000027568 Trauma and Stressor Related disease Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 1
- 208000022257 bipolar II disease Diseases 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 claims 1
- 239000003557 cannabinoid Substances 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000012601 choreatic disease Diseases 0.000 claims 1
- 201000006145 cocaine dependence Diseases 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 229910052732 germanium Inorganic materials 0.000 claims 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 claims 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 1
- 229960000240 hydrocodone Drugs 0.000 claims 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 1
- 229960001410 hydromorphone Drugs 0.000 claims 1
- 206010020765 hypersomnia Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 208000015046 intermittent explosive disease Diseases 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 208000029790 metamphetamine dependence Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 229960002085 oxycodone Drugs 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 206010036596 premature ejaculation Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 208000022610 schizoaffective disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000001932 seasonal effect Effects 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662426980P | 2016-11-28 | 2016-11-28 | |
| US201762576435P | 2017-10-24 | 2017-10-24 | |
| US201762585016P | 2017-11-13 | 2017-11-13 | |
| PCT/IB2017/057418 WO2018096510A1 (en) | 2016-11-28 | 2017-11-27 | Heteroarylphenoxy benzamide kappa opioid ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3544972T3 true FI3544972T3 (fi) | 2023-06-02 |
Family
ID=60782279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP17818281.2T FI3544972T3 (fi) | 2016-11-28 | 2017-11-27 | Heteroaryylifenoksibentsamidi-kappa-opioidiligandeja |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10316021B2 (enExample) |
| EP (1) | EP3544972B8 (enExample) |
| JP (1) | JP7051853B2 (enExample) |
| CN (1) | CN110234638B (enExample) |
| AU (1) | AU2017365123B2 (enExample) |
| DK (1) | DK3544972T3 (enExample) |
| ES (1) | ES2947293T3 (enExample) |
| FI (1) | FI3544972T3 (enExample) |
| HR (1) | HRP20230518T1 (enExample) |
| HU (1) | HUE061945T2 (enExample) |
| IL (1) | IL266962B (enExample) |
| MX (1) | MX389806B (enExample) |
| PH (1) | PH12019501172A1 (enExample) |
| PL (1) | PL3544972T3 (enExample) |
| PT (1) | PT3544972T (enExample) |
| RS (1) | RS64258B1 (enExample) |
| TW (1) | TWI720272B (enExample) |
| WO (1) | WO2018096510A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018154118A2 (en) * | 2017-02-24 | 2018-08-30 | Reinmueller Viktoria | Novel aromatic compounds |
| AU2018223177B2 (en) * | 2017-02-24 | 2024-05-02 | Xeniopro GmbH | Aromatic compounds which enhance notch signaling, for use in therapy |
| US11266627B1 (en) | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN111233768B (zh) * | 2020-03-18 | 2021-08-03 | 徐州圣元化工有限公司 | 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸乙酯的制备方法 |
| MX2021013934A (es) * | 2020-04-05 | 2021-12-15 | Pfizer | Compuestos y metodos para el tratamiento de covid-19. |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| EP4489748A1 (en) * | 2022-03-07 | 2025-01-15 | Janssen Pharmaceuticals, Inc. | Pure forms of crystalline aticaprant |
| CA3254546A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | COMPOSITIONS CONTAINING ATICAPRANT |
| CN119156211A (zh) * | 2022-03-07 | 2024-12-17 | 杨森制药公司 | 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰 |
| US20250353832A1 (en) * | 2022-10-12 | 2025-11-20 | Adama Makhteshim Ltd. | Process for the preparation of aminopyridazine derivatives |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US6420415B1 (en) | 1998-09-21 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Thiol compounds, their production and use |
| JP2000159747A (ja) | 1998-09-21 | 2000-06-13 | Takeda Chem Ind Ltd | 新規チオ―ル誘導体、その製造法および用途 |
| IT1303737B1 (it) | 1998-11-11 | 2001-02-23 | Smithkline Beecham Spa | Derivati fenilpiperidinici procedimento per la loro preparazione eloro uso come ligandi del recettore orl-1. |
| PT2208727E (pt) | 2002-09-19 | 2012-10-11 | Lilly Co Eli | Éteres diarílicos como antagonista do receptor opióide |
| US7365209B2 (en) | 2003-02-11 | 2008-04-29 | Pharmacopeia, Inc. | Nitrogen heterocycle biaryls for osteoporosis and other diseases |
| EP1606275B1 (en) | 2003-03-07 | 2008-08-27 | Eli Lilly And Company | Opioid receptor antagonists |
| JP4736043B2 (ja) | 2003-03-14 | 2011-07-27 | 小野薬品工業株式会社 | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| US8188277B2 (en) | 2004-08-06 | 2012-05-29 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compounds for suppressing the generation of collagen |
| EP1849835B1 (en) | 2005-02-18 | 2017-08-30 | Nippon Soda Co., Ltd. | Organic-inorganic composite body |
| RU2008140144A (ru) | 2006-03-10 | 2010-04-20 | Оно Фармасьютикал Ко., Лтд. (Jp) | Азотосодержащее гетероциклическое производное и фармацевтическое средство, включающее такое производное в качестве активного ингредиента |
| PL2001456T3 (pl) | 2006-04-04 | 2010-05-31 | Emodys Gmbh | Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych |
| US7709522B2 (en) | 2008-01-22 | 2010-05-04 | Eli Lilly And Company | Kappa selective opioid receptor antagonist |
| EP2257536A4 (en) | 2008-02-14 | 2011-03-23 | Amira Pharmaceuticals Inc | CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS |
| CR11559A (es) | 2008-03-25 | 2010-10-20 | Lilly Co Eli | Antagonista del receptor opioide selectivo kappa |
| US8048895B2 (en) | 2008-04-18 | 2011-11-01 | Research Triangle Institute | Kappa opioid receptor ligands |
| AU2009262068C1 (en) | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| EP2379524A1 (en) | 2008-12-18 | 2011-10-26 | Boehringer Ingelheim International GmbH | Serotonin 5-ht2b receptor inhibitors |
| HN2010001319A (es) | 2009-01-26 | 2013-01-15 | Lilly Co Eli | Antagonista del receptor opioide selectivo kappa |
| WO2013059648A1 (en) | 2011-10-21 | 2013-04-25 | Neurotherapeutics Pharma, Inc. | 2,3,5 trisubstituted aryl and heteroaryl amino derivatives, compositions, and methods of use |
| EP2903966A1 (en) | 2012-10-02 | 2015-08-12 | Merck Patent GmbH | Pyrrolidines |
| WO2015109080A1 (en) | 2014-01-15 | 2015-07-23 | Research Triangle Institute | Kappa-opioid receptor selective opioid receptor antagonists |
| US10118896B2 (en) | 2014-11-26 | 2018-11-06 | University Of Kansas | Antagonists of the kappa opioid receptor |
-
2017
- 2017-11-22 US US15/820,679 patent/US10316021B2/en active Active
- 2017-11-27 HR HRP20230518TT patent/HRP20230518T1/hr unknown
- 2017-11-27 EP EP17818281.2A patent/EP3544972B8/en active Active
- 2017-11-27 PL PL17818281.2T patent/PL3544972T3/pl unknown
- 2017-11-27 CN CN201780084763.0A patent/CN110234638B/zh active Active
- 2017-11-27 AU AU2017365123A patent/AU2017365123B2/en active Active
- 2017-11-27 PT PT178182812T patent/PT3544972T/pt unknown
- 2017-11-27 ES ES17818281T patent/ES2947293T3/es active Active
- 2017-11-27 TW TW106141134A patent/TWI720272B/zh active
- 2017-11-27 RS RS20230453A patent/RS64258B1/sr unknown
- 2017-11-27 WO PCT/IB2017/057418 patent/WO2018096510A1/en not_active Ceased
- 2017-11-27 HU HUE17818281A patent/HUE061945T2/hu unknown
- 2017-11-27 MX MX2019006220A patent/MX389806B/es unknown
- 2017-11-27 FI FIEP17818281.2T patent/FI3544972T3/fi active
- 2017-11-27 DK DK17818281.2T patent/DK3544972T3/da active
- 2017-11-27 JP JP2019528746A patent/JP7051853B2/ja active Active
-
2019
- 2019-05-28 IL IL266962A patent/IL266962B/en unknown
- 2019-05-28 PH PH12019501172A patent/PH12019501172A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180148432A1 (en) | 2018-05-31 |
| TW201831460A (zh) | 2018-09-01 |
| TWI720272B (zh) | 2021-03-01 |
| EP3544972B8 (en) | 2023-06-07 |
| CN110234638B (zh) | 2022-10-21 |
| EP3544972B1 (en) | 2023-04-26 |
| AU2017365123B2 (en) | 2022-02-17 |
| ES2947293T3 (es) | 2023-08-04 |
| JP7051853B2 (ja) | 2022-04-11 |
| JP2019535799A (ja) | 2019-12-12 |
| MX2019006220A (es) | 2019-10-07 |
| RS64258B1 (sr) | 2023-07-31 |
| CN110234638A (zh) | 2019-09-13 |
| MX389806B (es) | 2025-03-20 |
| US10316021B2 (en) | 2019-06-11 |
| IL266962A (en) | 2019-07-31 |
| CA3045242A1 (en) | 2018-05-31 |
| NZ754862A (en) | 2024-11-29 |
| IL266962B (en) | 2022-02-01 |
| PH12019501172A1 (en) | 2019-12-11 |
| AU2017365123A1 (en) | 2019-07-11 |
| DK3544972T3 (da) | 2023-05-30 |
| PL3544972T3 (pl) | 2023-07-24 |
| PT3544972T (pt) | 2023-06-20 |
| HUE061945T2 (hu) | 2023-09-28 |
| HRP20230518T1 (hr) | 2023-08-04 |
| WO2018096510A1 (en) | 2018-05-31 |
| EP3544972A1 (en) | 2019-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230518T1 (hr) | Heteroarilfenoksibenzamidni opioidni ligandi kapa | |
| JP7186256B2 (ja) | Ｔｒａｉｌ誘導のためのファーマコフォア | |
| RU2008139481A (ru) | Новые 1,4-диаза-бицикло[3.2.2]нонил-оксадиазолильные производные и их медицинское применение | |
| MX386258B (es) | Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas | |
| CA2470476A1 (en) | Pyrrolidine and piperidine derivates as nk1 antagonists | |
| CN112574196A (zh) | 调节激酶的1H-吡咯并[2,3-b]吡啶衍生物的合成 | |
| US8895729B2 (en) | Process for making thienopyrimidine compounds | |
| JP2009533393A5 (enExample) | ||
| JP2017524019A (ja) | Ｎｒ２ｂ受容体阻害剤としてのトリアゾール | |
| US20260028324A1 (en) | Nitric oxide releasing prodrugs of mda and mdma | |
| EP4424370A3 (en) | 7-phenoxy-n-(3-azabicyclo[3.2.1loctan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of alzheimer's disease | |
| RU2007106970A (ru) | Новые хромен-2-оновые производные и их применение в качестве ингибиторов обратного захвата моноаминовых нейромедиаторов | |
| AU2020334489A1 (en) | Salt and crystal form of compound having agonistic activity to S1P5 receptor | |
| JP2018517768A (ja) | ３−ビシクロ［３．２．０］ヘプ−３−エン−６オンエンの鏡像異性体の分離 | |
| RU2008129865A (ru) | Новые производные хромен-2-она и их применение в качестве ингибиторов обратного захвата нейромедиаторов моноаминов | |
| BRPI0508952A (pt) | composto, formulação farmacêutica, uso de um composto, processo para a preparação de compostos, e, método para tratar doença | |
| US8080655B2 (en) | Methods of making efavirenz and intermediates thereof | |
| JP2010513391A5 (enExample) | ||
| Zasukha et al. | The first synthesis of chiral dialkylamines with α, α-difluoroethers fragments | |
| PH12015500059A1 (en) | Pieprazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one | |
| SG11201407309XA (en) | Compositions and methods for the treatment of epilepsy | |
| Rakhimova et al. | Efficient catalytic synthesis of N-cycloalkyl-1, 5, 3-dithiazepanes | |
| EP1894921A3 (en) | 9, 10-Alpha, Alpha-Oh-Taxane analogs and methods for production thereof | |
| JP2008502650A5 (enExample) | ||
| JP5585087B2 (ja) | ヒドロキシアルキルトリエチレンジアミン類の製造方法 |